Skip to content
Toggle Open Icon-1
menu-close
  • There are no suggestions because the search field is empty.
Toggle Open Icon-1
menu-close

Advisory Briefs

The FTC-Express Scripts Settlement

know more

The FTC-Express Scripts Settlement: A Strategic Inflection Point for Pharmaceutical Manufacturers 

Given the settlement’s broader implications for pricing, access, and channel economics, Curatio Advisors convened industry leaders to examine the following: 

  • FTC-ESI CoverThe longstanding linkage between formulary access and high-WAC/high-rebate structures is under structural scrutiny. 
  •  Transparency-driven shifts toward fee-based PBM compensation will redistribute margin capture and bargaining leverage 
  •  Manufacturers that proactively model portfolio exposure and contract architecture scenarios will be positioned to shape negotiations rather than react to structural change. 

Download Advisory Brief

Curatio Scientia Advisors releases the “2023 Patient Access: State Legal and Regulatory Environment Survey”

Given the dynamic nature of state government activity we sought to validate the following:

  • Patient access to prescription drug therapy is greatly affected by various state and local policy and regulatory parameters.
  • There is no formalized process or aggregating compendium, at the state level, specifically monitoring policy and regulatory parameters that impact patient access to, and affordability of, drug therapies.
  • Timely insights into legislation and regulations pertaining to patient access, particularly for high-cost drug therapies will enable more effective decisions regarding the patient’s journey and drug product lifecycle.